The reagents and knowledge that are generated in our programs are made available to the neurofibromatosis community to ensure discoveries are advanced as quickly as possible.
Fueling your Research:
Development of therapies for human disease remains dependent on well-characterized and validated model systems. Slow growing histologically benign tumors such as neurofibromas are challenging to grow in typical culture conditions. As a result, the scientific field has been without reproducible, well-characterized cell culture model systems for neurofibromas. A team of researchers from the University of Florida, the National Center for Advancing Translational Sciences (NCATS), and Sage Bionetworks with support from the Neurofibromatosis Therapeutic Acceleration Program (NTAP) at Johns Hopkins, have developed and characterized a set of immortalized patient derived plexiform neurofibromas Schwann cells in an initial effort to create a series of cells that represent the genetic diversity of human cutaneous tumors.
Li et al , Laboratory Investigation, 2016 Oct; 96:1105–1115. PMID: 27617404
Ferrer et al, Scientific Data, 2018, 5:180106. PMID: 29893754
These invaluable tools for developing therapeutics for the treatment of neurofibromas, and possibly other diseases, and are now available for ordering from ATCC! Characterization information is available for viewing at Synapse.
NTAP is offering the opportunity for up to a 100% reimbursement of your purchase of these cells from ATCC!
|ATCC Part #||Product Description||Cell Type|
|CRL-3387||hTERT ipNF05.5 (mixed clones)||Human plexiform neurofibroma|
|CRL-3388||hTERT ipNF05.5||Human plexiform neurofibroma|
|CRL-3389||hTERT ipNF95.6||Human plexiform neurofibroma|
|CRL-3390||hTERT ipNF95.11b C||Human plexiform neurofibroma|
|CRL-3391||hTERT ipnNF95.11c||Human Schwann cell, NF1 donor|
|CRL-3392||hTERT ipn02.3 2λ||Human Schwann cell, non-NF1 donor|
To order cells from ATCC:
- Go to https://www.atcc.org
- Create a user profile (if a new user)
- Establish a customer account (if new customer)
- Order the desired cells in the table above at ATCC
To begin the reimbursement process*, after ordering the cells:
- Download the attached application, carefully review the reimbursement guidelines, and fill out.
- Within 90 days of your purchase, return your completed application along with a copy of your invoice and proof of payment to firstname.lastname@example.org.
*Purchasers from government agencies should not use the reimbursement application, but rather contact NTAP directly at email@example.com with their request for a reimbursement.
Through exogenous expression of human telomerase reverse transcriptase (hTERT) and murine cyclin-dependent kinase (mCdk4) using retroviral (and subsequently lentiviral) vectors carrying the hTERT and mCdk4 genes, normal (NF1 wild-type, +/+), neurofibroma-derived Schwann cells that were heterozygous (+/-) for NF1 mutation, and homozygous (-/-) for NF1 mutation, were immortalized. In-depth characterization of the immortalized cells entailed real time PCR for hTERT and mCdk4, NF1 mutational analysis, and studies for karyotyping, cell authentication, contact inhibition, proliferation rate and doubling time, apoptosis, microsatellite instability, and tumorigenicity. To learn more and view characterization data, click here
Human NF1 Associated Cutaneous Neurofibroma derived Induced Pluripotent Stem Cells (iPSCs) now available to the research community
Stem cells are cells early in their development before they have ‘been assigned’ a specific purpose (e.g. red blood cells to carry oxygen, white blood cells to fight infection). A group of researchers from the Germans Trias i Pujol Research Institute (IGTP) in Badalona (Barcelona), Spain, in collaboration with researchers from the Center for Regenerative Medicine in Barcelona (CMR[B]) have produced the first reprogrammed cutaneous neurofibroma-derived NF1(-/-) and NF1+/- cells into induced pluripotent stem cells (iPSCs). This is a critical accomplishment as it creates a non-perishable source of cells not generally available for slow growing tumors that can be used in experiments requiring large amounts of cells such as drug screening studies. Furthermore the versatile nature of iPSCs will enable biological studies and drug testing at different stages of cellular development, which will ultimately improve our understanding of the relative contribution of each cell type to tumorigenesis and the effects of a drug treatment at each step of disease development.
These iPSCs are now available for ordering and can be accessed by clicking here.